Close this search box.

The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol.

View Graphic

Leave a Reply

Your email address will not be published. Required fields are marked *